Metabolic effects of <i> <scp>L</scp> actobacillus reuteri </i> <scp>DSM</scp> 17938 in people with type 2 diabetes: <scp>A</scp> randomized controlled trial

Abstract

Intake of L. reuteri DSM 17938 for 12 weeks did not affect HbA1c in people with type 2 diabetes on insulin therapy; however, L. reuteri improved insulin sensitivity in a subset of participants and we propose that high diversity of the gut microbiota at baseline may be important.